Document is current
Any future updates will be listed below
-
Authors
Gonzalez, Victoria https://orcid.org/0000-0002-6788-2939
Lobb, Briallen
Côté, Jacob
Bhuinya, Arkadeb
Tubb, Adriana G. https://orcid.org/0009-0005-4571-0158
Nuthalapati, Stephen S. https://orcid.org/0009-0003-8006-1080
Asavajaru, Akarin
Zhou, Yan https://orcid.org/0000-0002-4706-1543
Misra, Vikram https://orcid.org/0000-0001-6818-7156
Falzarano, Darryl https://orcid.org/0000-0002-8805-8068
Sweeney, Trevor R.
Gobeil, Sophie M. C. https://orcid.org/0000-0002-0057-2477
Wang, Linfa https://orcid.org/0000-0003-2752-0535
Doxey, Andrew C.
Banerjee, Arinjay https://orcid.org/0000-0002-2821-8357
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-195787)
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 16 June 2025
First Online: 1 July 2025
Competing interests
: A.B. is a co-inventor of the Efk3B cell line that is sold through Kerafast, USA. S.G. is named in a patent regarding coronavirus monoclonal antibodies (WO2022060906A1). The invention provides methods for using the inventive antibodies in prophylactic and/or therapeutic methods to prevent or treat coronavirus infection. The remaining authors declare no competing interests.
